Most comparative trials compared tirzepatide against semaglutide at a dose of 1 mg, and head-to-head evaluations with higher doses of semaglutide 2.4 mg (approved for obesity), or with other oral GLP-1 agents are currently lacking. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.